



MEETING ABSTRACT

Open Access

The pharmacotherapy of depression with EPA

Basant K Puri

From 1st International Congress on Neurobiology and Clinical Psychopharmacology and European Psychiatric Association Conference on Treatment Guidance
Thessaloniki, Greece. 19-22 November 2009

This lecture considers the pharmacotherapy of depression with EPA under the following headings:

- Epidemiological evidence
- Biochemical evidence
- First trial of pure EPA in severe treatment-resistant depression
- Subsequent randomized double-blind placebo-controlled trials
- Putative mechanisms.

Results obtained from our own group, including structural neuroimaging and ³¹-phosphorus neurospectroscopy findings, showing an association of EPA treatment of depression with a marked decrease in cerebral phosphodiesterases, a marked increase in cerebral phosphomonoesters and reduced lateral ventricular volume, will also be presented.

Published: 22 April 2010

doi:10.1186/1744-859X-9-S1-S23

Cite this article as: Puri: The pharmacotherapy of depression with EPA.
Annals of General Psychiatry 2010 **9**(Suppl 1):S23.

**Submit your next manuscript to BioMed Central
and take full advantage of:**

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at
www.biomedcentral.com/submit



Imperial College London, UK



© 2009 Puri; licensee BioMed Central Ltd.